Key Players Contribution to the Global Inhalable Drugs Market

The global inhalable drug market is anticipated to grow at a CAGR of 3.7% over the forecast period (2020-2026). The key factors that drive the growth of the market include the continuous contribution by the key players operating in the market. Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Bausch Health Companies Inc., are some of the prominent players operating in the global inhalable drugs industry. Product launches, innovations, mergers, and acquisitions are some of the strategies adopted by the key players.

Browse the full report description of "Global Inhalable Drugs Market Size, Share & Trends Analysis Report by Application (Respiratory Diseases and Non-Respiratory Diseases), By Route of Administration (Nasal and Mouth), and Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/inhalable-drugs-market

Some of the key activities include-

• In May 2019, GlaxoSmithKline Plc added a novel drug Trelegy to its lung medicine division. 
• Further, in April 2019, Cipla Ltd. announced the launch of the novel drug Niveoli. It is an extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to the small airways. Niveoli is mainly used in the treatment of diseases such as asthma and chronic obstructive pulmonary disorder (COPD). 
• Similarly, in March 2019, Breath Therapeutics announced the beginning of global Phase 3 trials for the treatment of Bronchiolitis Obliterans Syndrome (BOS) via inhalable drugs. 

Thus, such activities adopted by the key players are estimated to enhance the growth of the market over the forecast period.

Market Coverage

• Market number available for – 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Application and By Route of Administration
• Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
• Competitive Landscape- Boehringer Ingelheim International GmbH, Pfizer Inc., Novartis International AG, AstraZeneca Plc, GlaxoSmithKline Plc, and Johnson & Johnson Services Inc.

Key questions addressed by the report

• What is the market growth rate?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID-19

o Most affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Inhalable Drugs Market – Segmentation

By Application

• Respiratory Diseases
• Non- Respiratory Diseases

By Route of Administration 

• Nasal
• Mouth 

Global Inhalable Drugs Market – Segmentation by Region 

North America

• United States
• Canada

Europe

• UK
• Germany
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/inhalable-drugs-market